Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

36.55 USD +0.07 (+0.19%)
Official Closing Price Updated: 7:59 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Pfizer

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
From GlobeNewswire News Releases
Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S.... 
From Business Wire News Releases
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Research for Immunotherapy Combinations with Paclitaxel Helping in Breast Cancer Fight
FN Media Group Presents USA News Group News Commentary 
From PR Newswire
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
From GlobeNewswire News Releases
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) today announced initial data from their ongoing German Phase 1/2, open-label, non-randomized, non-placebo-controlled,... 
From Business Wire News Releases
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
From GlobeNewswire News Releases
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2,... 
From Business Wire News Releases
Wearable Medical Devices Give Patients the Ability to be More Independent
FinancialBuzz.com News Commentary 
From PR Newswire
BioAtla Raises $72.5 Million In Series D Financing
Proceeds will advance CAB-AXL and CAB-ROR2 clinical programs into Phase 2 trials, CAB-CTLA-4 Phase 1 trial, and additional CAB development programs 
From PR Newswire
Basilea reports the launch of antifungal Cresemba® (isavuconazole) in Taiwan, triggering the second milestone payment related to Asia-Pacific
From GlobeNewswire News Releases
Syneos Health Signs New Service Agreement With Pfizer
From GlobeNewswire News Releases
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Anticipated large, global Phase 2b/3 safety and efficacy study may begin as early as July 2020 
From GlobeNewswire News Releases
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program... 
From Business Wire News Releases
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
Pfizer Inc. (NYSE: PFE) announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health... 
From Business Wire News Releases
ViiV Healthcare Announces Superior Efficacy of Investigational, Long-Acting Injectable Formulation of Cabotegravir Dosed Every Two Months Over Daily Oral PrEP
ViiV HC announces superior efficacy of investigational long-acting injectable formulation of cabotegravir dosed every two months over daily oral PrEP 
From Business Wire News Releases
New Innovative Brands Look to Disrupt Big Tobacco with Better-For-You Alternatives
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Innovative Brands Look to Disrupt big Tobacco With Better-for-you Alternatives
FN Media Group Presents Microsmallcap.com Market Commentary 
From PR Newswire
Regulators Move to Remove Restriction on Some Uses of Psilocybin
FinancialBuzz.com News Commentary 
From PR Newswire
Mission Raises $15m and Expands its Relationship with Pfizer
Mission Therapeutics Raises $15m and Expands its Relationship with Pfizer 
From Business Wire News Releases
ViiV Healthcare Announces US FDA Approval for Rukobia (fostemsavir), a First-in-Class Treatment for HIV in Adults With Few Treatment Options Available
US FDA approves ViiV Healthcare's Rukobia (fostemsavir), a first-in-class treatment for HIV in adults with few treatment options available 
From Business Wire News Releases
Thinking about buying stock in Pfizer Inc, Opko Health, Macy's, Spirit Airlines, or MGM Resorts?
InvestorsObserver issues critical PriceWatch Alerts for PFE, OPK, M, SAVE, and MGM. 
From PR Newswire
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
From GlobeNewswire News Releases
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 study of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program,... 
From Business Wire News Releases
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for UK-based media 
From PR Newswire
Pfizer Declares Third-Quarter 2020 Dividend
The board of directors of Pfizer Inc. (NYSE:PFE) today declared a 38-cent third-quarter 2020 dividend on the company’s common stock, payable September 1, 2020, to holders of the Common Stock of record... 
From Business Wire News Releases
Psychedelic Medicine Stocks Garner Serious Investor Interest
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Psychedelic Medicine Stocks Garner Serious Investor Interest
FN Media Group Presents Microsmallcap.com Market Commentary 
From PR Newswire
Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa
Pfizer Inc. (NYSE: PFE) and Wellcome today announced the launch of the Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR), a new multi-year, public-private... 
From Business Wire News Releases
Clinical Trials For New Therapies Providing Hope For Metastatic Breast Cancer Patients
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.